Intellectual Property Watch examines WHO working group on drug development financing

NewsGuard 100/100 Score

Intellectual Property Watch examines the wrap-up of a WHO meeting of experts discussing innovative ways to finance research and development for products to treat diseases in developing countries and reports that recommendations by the group are expected to be released within a few weeks. 

Intellectual Proprety Watch outlines several strategies discussed during the meeting, including taxes and donations: "Money-making models discussed by the working group seemed to heavily revolve around taxes, from the drug-procurement group UNITAID's tax on airline tickets, to the 'Tobin tax' that proposes a small surcharge on financial transactions, to other suggested taxes on goods like tobacco or pharmaceuticals. There was also discussion of voluntary donations, perhaps through a fund, a source told Intellectual Property Watch."

The publication also examines a recent WHO progress report (.pdf) on the agency's global strategy for pubic health, innovation and intellectual property. "The implementation of the global strategy is focusing on three areas: innovation and access, capacity building, and resource mobilisation and sustainable financing, Precious Matsoso [of the WHO] said ... Initial areas, according to the global strategy report seem to be heavily focussed on technology transfer and capacity building," the publication writes (Mara, 12/7).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis